Sep 2026· Journal of Translational Medicine· 0 citations
TL;DR
This review summarizes HIF-targeted strategies at the molecular, clinical, and emerging therapeutic levels, with a focus on the translational progress of lead candidates such as 32-134D and PX-478.
Abstract
Hypoxia-inducible factor (HIF) is a key driver of ocular neovascular diseases. We systematically discuss its regulatory mechanisms and pathological roles in diabetic retinopathy (DR), retinopathy of prematurity (ROP), and neovascular age-related macular degeneration (nAMD). Upon integration of diverse upstream stimuli—including hypoxia, hyperglycemia, oxidative stress, and inflammatory signals—HIF orchestrates a downstream effector network that drives aberrant neovascularization, vascular leakage, fibrotic remodeling, and neuroretinal degeneration. Current anti-vascular endothelial growth factor (Anti-VEGF) therapies, which block only a single downstream factor, are constrained by inadequate response and resistance. Therefore, pharmacological targeting of the upstream “master switch” HIF represents a promising strategy for achieving broader therapeutic efficacy. In this review, we summarize HIF-targeted strategies at the molecular, clinical, and emerging therapeutic levels,with a focus on the translational progress of lead candidates such as 32-134D and PX-478. Furthermore, the present review highlights the dual role of HIF in physiological vascular development and pathological neovascularization, emphasizing that precise regulation of timing, cell type and microenvironment is critical for therapeutic success. Finally, the limitations of current HIF-targeted therapies and future directions are discussed. Collectively, these insights may support the development of more precise and effective therapies for ocular neovascular diseases.
Diabetic retinopathy (DR) is a leading cause of preventable blindness in adults of working age. Anti-vascular endothelial growth factor (anti-VEGF) therapy is the reference standard for diabetic macular edema (DME), yet in randomized cohorts, approximately 30-40% of DME eyes still show central macular thickening after...
Hai Chen, Wei Chen· American journal of translat...· 0 citations
Retinal vascular fibrosis is a pathological hallmark of advanced diabetic retinopathy (DR), marking the transition from reversible vascular dysfunction to irreversible structural damage. Emerging evidence has established angiopoietin-2 (Ang-2) as a crucial initiating factor in retinal vascular fibrosis. In the diabetic...
Xin-Ping Yan, Ying-Shi Zou, Tian-Yi Luo et al.· Survey of ophthalmology· 0 citations
Ocular neovascularization (NV) causes blindness, yet anti-VEGF therapy has limited efficacy. Myc controls endothelial cell (EC) proliferation and activation, however, its pathological role in ocular NV and therapeutic value remain unclear. In this study, we found that Myc was markedly upregulated in neovascular ECs (NV...
Bo Tang, Quan Zhang, Ya-Nan He et al.· Biomaterials· 0 citations
Although anti-angiogenic therapy has been widely used in the treatment of solid tumors, angiogenesis inhibition alone frequently induces acquired resistance and exacerbates tumor hypoxia, paradoxically promoting tumor progression. The concept of tumor vascular normalization has offered a new perspective to address this...
Qiang Huang, Yu-Jing Guo, Shan-Yu Yin et al.· Frontiers in Immunology· 0 citations
Highlights What are the main findings? This review summarizes the cellular and molecular mechanisms of ocular fibrosis. This review also summarizes current therapies and their limitations, as well as potential treatments in pre-clinical studies and clinical trials. What are the implications of the main findings? Unders...
Jia-Yu Ning, Brian Wang, M. Yamamoto et al.· Cells· 0 citations